Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome?
Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
Inhibitors of ABL and the ABL-T315I Mutation.
New therapeutic approaches and prognostic factors in chronic myeloid leukemia.
Labial fusion: a rare complication of chronic graft-versus-host disease.
Chronic myeloid leukemia presenting as vulvar hematoma.
Nilotinib.
[Association between HLA and leukemia in a mixed Brazilian population]
A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia.
Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation.
Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Transformation by Oncogenic Mutants and Ligand-Dependent Activation of FLT3 Wild-type Requires the Tyrosine Residues 589 and 591.
Pre-transplant depression as risk factor for survival of patients undergoing allogeneic haematopoietic stem cell transplantation.
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
The role of beta-catenin in chronic myeloproliferative disorders.
Anti-Bcl2 therapy in chronic myelogenous leukemia.
The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations.